Afsheen N. Iqbal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Afsheen N. Iqbal has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alex Makhnin
Memorial Sloan Kettering Cancer Center 1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine New York, New York
29 shared publications - Andrew J. Plodkowski
Memorial Sloan Kettering Cancer Center, New York, USA
29 shared publications - Arielle Elkrief
Axe cancer, Centre de recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada
29 shared publications - Franziska Michor
Department of Data Science, Dana-Farber Cancer Institute
29 shared publications - Gregory J. Riely
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
29 shared publications - Helena Alexandra Yu
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
29 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 4. A. Median progression-free survival and B. Overall survival for patients enrolled in the acquired resistance study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 4. A. Median progression-free survival and B. Overall survival for patients enrolled in the acquired resistance study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 1. Dose modifications of Combination Osimertinib and Dacomitinib (initial therapy study).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 1. Dose modifications of Combination Osimertinib and Dacomitinib (initial therapy study).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 3. A. Median progression-free survival and B. Overall survival for patients enrolled in the initial therapy study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 3. A. Median progression-free survival and B. Overall survival for patients enrolled in the initial therapy study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 2. Dose modifications of Dacomitinib +/- Osimertinib (acquired resistance study).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 2. Dose modifications of Dacomitinib +/- Osimertinib (acquired resistance study).
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 4. A. Median progression-free survival and B. Overall survival for patients enrolled in the acquired resistance study
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 4. A. Median progression-free survival and B. Overall survival for patients enrolled in the acquired resistance study
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 4. A. Median progression-free survival and B. Overall survival for patients enrolled in the acquired resistance study
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 4. A. Median progression-free survival and B. Overall survival for patients enrolled in the acquired resistance study
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 1. Dose modifications of Combination Osimertinib and Dacomitinib (initial therapy study).
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 1. Dose modifications of Combination Osimertinib and Dacomitinib (initial therapy study).
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Purpose:Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and combination therapy with dual EGFR TKIs may prevent or reverse on-target resistance.Patients and Methods:We conducted two prospective, phase I/II trials assessing combination osimertinib and dacomitinib to address on-target resistance in the primary and acquired resistance settings. In the initial therapy study, patients received dacomitinib and osimertinib in combination as initial therapy. In the acquired resistance trial, dacomitinib with or without osimertinib was administered to patients with EGFR-mutant lung cancers with disease progression on osimertinib alone and evidence of an acquired EGFR second-site mutation.Results:Cutaneous toxicities occurred in 93% (any grade) of patients and diarrhea in 72% (any grade) with the combination. As initial therapy, the overall response to the combination was 73% [95% confidence interval (CI), 50%–88%]. No acquired secondary alterations in EGFR were observed in any patients at progression. In the acquired resistance setting, the overall response was 14% (95% CI, 1%–58%).Conclusions:We observed no acquired secondary EGFR alterations with dual inhibition of EGFR as up-front treatment, but this regimen was associated with greater toxicity. The combination was not effective in reversing acquired resistance after development of a second-site acquired EGFR alteration. Our study highlights the need to develop better strategies to address on-target resistance in patients with EGFR-mutant lung cancers.
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Purpose:Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and combination therapy with dual EGFR TKIs may prevent or reverse on-target resistance.Patients and Methods:We conducted two prospective, phase I/II trials assessing combination osimertinib and dacomitinib to address on-target resistance in the primary and acquired resistance settings. In the initial therapy study, patients received dacomitinib and osimertinib in combination as initial therapy. In the acquired resistance trial, dacomitinib with or without osimertinib was administered to patients with EGFR-mutant lung cancers with disease progression on osimertinib alone and evidence of an acquired EGFR second-site mutation.Results:Cutaneous toxicities occurred in 93% (any grade) of patients and diarrhea in 72% (any grade) with the combination. As initial therapy, the overall response to the combination was 73% [95% confidence interval (CI), 50%–88%]. No acquired secondary alterations in EGFR were observed in any patients at progression. In the acquired resistance setting, the overall response was 14% (95% CI, 1%–58%).Conclusions:We observed no acquired secondary EGFR alterations with dual inhibition of EGFR as up-front treatment, but this regimen was associated with greater toxicity. The combination was not effective in reversing acquired resistance after development of a second-site acquired EGFR alteration. Our study highlights the need to develop better strategies to address on-target resistance in patients with EGFR-mutant lung cancers.
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 3. A. Median progression-free survival and B. Overall survival for patients enrolled in the initial therapy study
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Supplemental Figure 3. A. Median progression-free survival and B. Overall survival for patients enrolled in the initial therapy study